SCHEMBL20328528

SCHEMBL20328528

N#CC(F)(F)C(F)(C(F)(F)C#N)C(F)(F)C#N

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9082213 0.82 ALDH1A1 (0.36) ALDH1A1TSHR
SCHEMBL250742 0.75
SCHEMBL9495942 0.75 ALDH1A1 (0.31) ALDH1A1TSHR
SCHEMBL4386192 0.75 ALDH1A1 (0.31) ALDH1A1TSHR
SCHEMBL20328527 0.75 ALDH1A1 (0.31) ALDH1A1TSHR
SCHEMBL250741 0.75
Ammonia Solution, Strong SCHEMBL7048356 0.72
SCHEMBL5013984 0.72
SCHEMBL5014889 0.72
SCHEMBL29032518 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10720665-B2 Lithium secondary battery including a perfluoro nitrile compound SOULBRAIN CO., LTD. (KR) 2020-07-21 US disclosed
EP-3312929-B1 ELECTROLYTE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME SOULBRAIN CO LTD (KR) 2019-04-17 EP disclosed
US-20180183100-A1 ELECTROLYTE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING SAME SOULBRAIN CO., LTD. (KR) 2018-06-28 US disclosed
US-20180183100-A1 ELECTROLYTE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING SAME SOULBRAIN CO., LTD. (KR) 2018-06-28 US disclosed
EP-3312929-A1 ELECTROLYTE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING SAME Soulbrain Co., Ltd. (KR) 2018-04-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180183100-A1 ELECTROLYTE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING SAME KCNN2, KCNK9, KCNB2 ALDH1A1 536/4885TSHR 4617/4885
US-10720665-B2 Lithium secondary battery including a perfluoro nitrile compound AFF4, FLNB, CACNA1B ALDH1A1 1618/4885TSHR 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.